Skip to content

NUTRA PHARMA CORP.: 10-Q/A filed 2012-12-12

What NUTRA PHARMA CORP. reported in its quarterly report amendment filed 2012-12-12 (fiscal Q3 2012): 23 published measures, 62 facts as tagged in accession 0001144204-12-067558.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2012-12-12
Fiscal period
fiscal Q3 2012
Accession
0001144204-12-067558 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NUTRA PHARMA CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-30190,796USD
At 2011-12-31229,305USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-30-3,952,229USD
At 2011-12-31-3,911,445USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-309,115USD
At 2011-12-310USD
At 2011-09-3026,138USD
At 2010-12-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-302,784USD92
2012-01-01 to 2012-09-30-1,425,464USD274
2011-07-01 to 2011-09-30-661,758USD92
2011-01-01 to 2011-09-30-1,898,034USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-569,545USD274
2011-01-01 to 2011-09-30-1,912,629USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-09-300USD274
2011-01-01 to 2011-09-301,028USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-30578,660USD274
2011-01-01 to 2011-09-301,939,795USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-09-30-35,456,969USD
At 2011-12-31-34,031,505USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-3043,260USD
At 2011-12-3154,509USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-244,798USD92
2012-01-01 to 2012-09-30-1,128,927USD274
2011-07-01 to 2011-09-30-668,925USD92
2011-01-01 to 2011-09-30-1,924,701USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-30130,915USD
At 2011-12-31158,175USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-07-01 to 2012-09-3039,772USD92
2012-01-01 to 2012-09-30114,963USD274
2011-07-01 to 2011-09-3023,248USD92
2011-01-01 to 2011-09-3071,738USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-304,125,692USD
At 2011-12-314,111,917USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-09-30850,772USD
At 2011-12-311,098,452USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2012-09-30117,800USD
At 2011-12-31117,800USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2012-07-01 to 2012-09-308,961USD92
2012-01-01 to 2012-09-3033,830USD274
2011-07-01 to 2011-09-30163,354USD92
2011-01-01 to 2011-09-30469,733USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2012-07-01 to 2012-09-30213,987USD92
2012-01-01 to 2012-09-301,044,748USD274
2011-07-01 to 2011-09-30791,776USD92
2011-01-01 to 2011-09-302,235,457USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-300USD92
2012-01-01 to 2012-09-303,046USD274
2011-07-01 to 2011-09-3017,255USD92
2011-01-01 to 2011-09-3087,239USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-30382,503,657shares
At 2011-12-31315,313,673shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2012-09-3016,621USD
At 2011-12-3116,621USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-09-30969,677USD
At 2011-12-31951,073USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-57,986USD92
2012-01-01 to 2012-09-30-296,537USD274
2011-07-01 to 2011-09-307,167USD92
2011-01-01 to 2011-09-3026,667USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-09-30270,000USD274
2011-01-01 to 2011-09-30159,500USD273

Inspect the source

Entity
NUTRA PHARMA CORP. / CIK 0001119643
Captured
2026-09-20T05:24:45.365Z
SEC response SHA-256
a9ccf17d1b07544de23a6dd72641e83d2b0b8f34b5c47b58fd5a236f1c887339

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001119643.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))